SMMT Stock: Price, Earnings History and SEC Filings
Summit Therapeutics Inc. (SMMT) last traded at $16.03, down 1.05% on the latest session and down 5.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.28 against an analyst estimate of $-0.26, a miss of 7.7%.
$16.03 -1.05%
1 month-5.20%
52-week high$29.23
52-week low$12.07
Volume3.51M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SMMT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 23, 2026 | $-0.28 | $-0.26 | -7.69% |
| Mar 2026 | Apr 30, 2026 | $-0.24 | $-0.33 | +27.27% |
| Dec 2025 | Feb 23, 2026 | $-0.29 | $-0.22 | -31.82% |
| Sep 2025 | Oct 20, 2025 | $-0.31 | $-0.14 | -121.43% |
SMMT beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for SMMT
SEC filing data is not available right now. You can search for SMMT on SEC EDGAR.
SMMT news
- Summit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI DealOct 30, 2026 · finance.yahoo.com
- AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales GrowthOct 30, 2026 · finance.yahoo.com
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsOct 26, 2026 · marketbeat.com
- Lunit and Summit to evaluate pathology platform for tumour analysisOct 26, 2026 · pharmaceutical-technology.com
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in ChinaOct 25, 2026 · finance.yahoo.com
- Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentOct 24, 2026 · finance.yahoo.com
- Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentOct 23, 2026 · finance.yahoo.com
- U.S. Treasury Wants to Rein In Deals for Chinese Biotech and AIOct 23, 2026 · finance.yahoo.com
About Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) is a US-listed public company on Nasdaq.